Answers are grounded in this paper and cite their sources.
Background: Phenylketonuria (PKU) is an inherited metabolic disease that is caused by loss-of-function mutations in the liver enzyme phenylalanine hydroxylase (PAH), which metabolizes blood phenylalanine (Phe) to tyrosine (Tyr). The result is the systemic accumulation of Phe in the body that can lead to neurotoxic effects if left untreated. Numerous mutations in PAH lead to the destabilization and misfolding of the enzyme that result in PKU. Methods: A cellular phenotypic assay was developed to identify compounds that could stabilize PAH and increase the conversion rate of Phe to Tyr. Screening hits were then used to design an exemplar compound which was scaled up and crystallized with purified enzyme to determine the PAH binding site, and also orally dosed to mice engineered with the most common mutation that causes PKU in humans, R408W. Results: Here, we report the discovery of a small-molecule chaperone that promotes stabilization of PAH R408W both in vitro and in vivo. Moreover, this molecule restores the endogenous metabolic pathway, thus normalizing the elevated blood Phe concentrations of the PAH R408W homozygous mice. Conclusions: These studies demonstrate in a preclinical mouse model that use of a drug-like small-molecule pharmacological chaperone can be a viable approach for the treatment of severe PKU.
No takes yet. Share an insight, caveat, or question.
Okamura et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: